Compare Kian Santang Muliatama Tbk. (RGAS) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kian Santang Muliatama Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Kian Santang Muliatama Tbk. trades at Rp114 (market cap 163.43B, 36.43M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Kian Santang Muliatama Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| RGAS | SCPI | |
|---|---|---|
Market Cap | 163.43B | 104.4B |
Volume | 36.43M | — |
Lot | 364.26K | — |
Turnover | 4B | — |
Average Price | 109.89 | — |
Value | 4B | — |
Indicative Equilibrium Price | 114 | — |
Indicative Equilibrium Volume | 5.9K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kian Santang Muliatama Tbk.
PT Kian Santang Muliatama Tbk (the Entity) was established based on the Notarial Deed of Artisa Khamelia Ramadiyanti, S.H., M.Kn., No. 634, dated November 28, 2018. The Entity started its commercial operations on 2019. The controlling party for the Company is Edy Nurhamid Amin.
Read more on RGAS →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
